UBS Keeps Their Buy Rating on CSL (CMXHF)


UBS Keeps Their Buy Rating on CSL (CMXHF)

Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio

Sutcliffe covers the Healthcare sector, focusing on stocks such as CSL, Resmed, and Ansell. According to TipRanks, Sutcliffe has an average return of 8.0% and a 58.91% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for CSL with a $204.46 average price target, which is a 20.63% upside from current levels. In a report released today, Citi also maintained a Buy rating on the stock with a A$345.00 price target.

CMXHF market cap is currently $81.73B and has a P/E ratio of 32.64.

Previous articleNext article

POPULAR CATEGORY

corporate

11914

tech

11464

entertainment

14737

research

6792

misc

15706

wellness

12003

athletics

15655